Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study - 27/01/22
Doi : 10.1016/j.jaad.2021.10.034
Pascal Joly, MD, PhD ⁎ 
and
and
French study Group on auto immune bullous skin diseases, and the French network of rare diseases in Dermatology (FIMARAD)∗
André Gillibert, MD,b Gérôme Bohelay, MD,c Karen Aouar, MD,a Saskia Ingen-Housz-Oro, MD,d Christophe Bedane, MD, PhD,e Clémence Lepelletier, MD,f Emmanuelle Tancrède Bohin, MD,f Manuelle Viguier, MD, PhD,g Nicolas Dupin, MD, PhD,h Sebastien Debarbieux, MD,i Denis Jullien, MD, PhD,j Gaelle Quereux, MD, PhD,k Cécile Morice, MD,l Antoine Mahe, MD,m Catherine Michel, MD,n Noemie Litrowski, MD,o Géraldine Jeudy, MD,p Marie Aleth Richard, MD, PhD,q Catherine Picard, MD, PhD,r Olivier Chosidow, MD, PhD,d Anne-Pham Ledard, MD, PhD,s Vivien Hebert, MD,a Sophie Duvert-Lehembre, MD,t Nadège Cordel, MD, PhD,u Marina Alexandre, MD,c Christelle Le Roux-Villet, MD,c and Frédéric Caux, MD, PhDcFrom the Department of Dermatology, Rouen University Hospital, Centre de référence des maladies bulleuses autoimmunes and Institut national de la santé et de la recherche médicale (INSERM) U1234,a and Department of Biostatistics, Centre Hospitalier Universitaire Rouen and INSERM U1219, Normandie University, Rouen, Franceb; Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Centre de référence des maladies bulleuses autoimmunes and INSERM UMR1125, Bobigny, Francec; Department of Dermatology, Henri Mondor University Hospital, Assistance Publique, Hopitaux de Paris (AP-HP), Créteil, Franced; Department of Dermatology, Limoges University Hospital, Limoges, Francee; Department of Dermatology, Saint Louis Hospital, AP-HP, Paris, Francef; Department of Dermatology, Centre de référence des maladies bulleuses autoimmunes and EA7509, Reims University Hospital, Reims, Franceg; Department of Dermatology, Cochin Hospital, AP-HP, Paris, Franceh; Department of Dermatology, Lyon sud Hospital, Hospices Civils de Lyon, Lyon, Francei; Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, Francej; Department of Dermatology, Nantes University Hospital, Nantes, Francek; Department of Dermatology, Caen University Hospital, Caen, Francel; Department of Dermatology, Colmar General Hospital, Colmar, Francem; Department of Dermatology, Mulhouse General Hospital, Mulhouse, Francen; Department of Dermatology, Le Havre General Hospital, le Havre, Franceo; Department of Dermatology, Dijon University Hospital, Dijon, Francep; CEReSS-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Dermatology Department, University Hospital Timone, Assistance Publique Hôpitaux de Marseille, APHM, 13385, Marseille, Franceq; Department of Dermatology, Bichat Hospital, AP-HP, Paris, Francer; Dermatology Department, INSERM U1053, University Hospital of Bordeaux, Hôpital Saint-André, Bordeaux, Frances; Department of Dermatology, Lille University Hospital, Lille, Francet; and Department of Dermatology and Clinical Immunology-Guadeloupe University Hospital, and Normandie University UNIROUEN, IRIB, U1234, Pointe à Pitre, France.u
André Gillibert, MD, Gérôme Bohelay, MD, Karen Aouar, MD, Saskia Ingen-Housz-Oro, MD, Christophe Bedane, MD, PhD, Clémence Lepelletier, MD, Emmanuelle Tancrède Bohin, MD, Manuelle Viguier, MD, PhD, Nicolas Dupin, MD, PhD, Sebastien Debarbieux, MD, Denis Jullien, MD, PhD, Gaelle Quereux, MD, PhD, Cécile Morice, MD, Antoine Mahe, MD, Catherine Michel, MD, Noemie Litrowski, MD, Géraldine Jeudy, MD, Marie Aleth Richard, MD, PhD, Catherine Picard, MD, PhD, Olivier Chosidow, MD, PhD, Anne-Pham Ledard, MD, PhD, Vivien Hebert, MD, Sophie Duvert-Lehembre, MD, Nadège Cordel, MD, PhD, Marina Alexandre, MD, Christelle Le Roux-Villet, MD, Frédéric Caux, MD, PhD
Department of Dermatology, Rouen University Hospital, Centre de référence des maladies bulleuses autoimmunes and INSERM U1234, Normandie University, Rouen, France
∗Correspondence to: Pascal Joly, MD, PhD, Department of Dermatology, Rouen University Hospital, Centre de référence des maladies bulleuses autoimmunes and INSERM U1234, Normandie University, 1 rue de Germont, 76031 Rouen, FranceDepartment of DermatologyRouen University HospitalCentre de référence des maladies bulleuses autoimmunes and INSERM U1234Normandie University1 rue de GermontRouen76031France
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : autoimmune bullous skin diseases, COVID-19, mortality, rituximab
| Drs Bohelay and Aouar contributed equally to this article. |
|
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved by the institutional review board of Rouen University Hospital (no. E2020-59). |
|
| Reprints not available from the authors. |
© 2021
Publié par Elsevier Masson SAS.
Vol 86 - N° 2
P. 494-497 - février 2022 Retour au numéro
Article précédent
- The disproportionate burden of electronic health record messages with image attachments in dermatology
- Ethan D. Borre, Matilda W. Nicholas
- Ethics of post-trial access to treatment in dermatology
- Sarah Nasser, Abraham M. Korman, Stephanie K. Fabbro
Bienvenue sur EM-consulte, la référence des professionnels de santé.